PDF下载 ( 1751 KB)
血清碱性磷酸酶与2型糖尿病合并非酒精性脂肪肝病的相关性分析
DOI: 10.3969/j.issn.1001-5256.2023.01.013
Association between serum alkaline phosphatase and type 2 diabetes mellitus with nonalcoholic fatty liver disease
-
摘要:
目的 探讨血清碱性磷酸酶(ALP)与2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD) 的相关性。 方法 选取2016年7月—2018年12月于江苏大学附属医院内分泌科住院的599例T2DM患者为研究对象。根据是否合并NAFLD分为NAFLD组(286例)和非NAFLD组(313例)，根据腹部超声检查结果将NAFLD患者分为轻度(111例)、中度(105例)、重度(70例)三组，比较各组间一般临床资料的差异。正态分布的计量资料两组间比较采用独立样本t检验，三组间比较采用方差分析；非正态分布计量资料两组间比较采用Mann-Whitney U检验；三组间比较使用Kruskal-Wallis H秩和检验，计数资料组间比较采用χ2检验。采用Pearson相关分析法和Spearman相关分析法分析ALP与临床指标的相关性。Logistic回归分析NAFLD的影响因素。 结果 NAFLD组高血压病史所占比例、收缩压、舒张压、BMI、腰围(WC)、空腹胰岛素(FIns)、空腹C肽、血尿酸、低密度脂蛋白胆固醇、TG、TC、稳态模型评估胰岛素抵抗指数(HOMA-IR)、ALT、AST、GGT、ALP均高于非NAFLD组(χ2= 7.864、t=-2.226、t=-3.800、t=-11.842、t=-9.150、Z=-6.173、t=-5.419、t=-4.957、t=-2.702、Z=-9.376、t=-3.016、Z=-5.794、Z=-6.737、Z=-4.389、Z=-7.764、t=-2.833，P值均＜0.05)。NAFLD组年龄、高密度脂蛋白胆固醇均低于非NAFLD组(t=2.184、Z=-5.273，P值均＜0.05)。NAFLD脂肪肝的严重程度(轻、中、重)与年龄(rs=0.140)、BMI(rs=0.239)、WC(rs=0.222)、FIns(rs=0.191)、HOMA-IR(rs=0.218)、ALT(rs=0.188)、AST(rs=0.279)、GGT(rs=0.202)、ALP(rs=0.361)呈正相关(P值均＜0.05)。在T2DM合并NAFLD患者中，ALP与糖化血红蛋白(r=0.149)、空腹血糖(r=0.146)、HOMA-IR(rs=0.132)、TC(r=0.151)、ALT(rs=0.210)、AST(rs=0.192)、GGT(rs=0.297)呈正相关(P值均＜0.05)。Logistic回归分析显示，ALP是T2DM患者发生NAFLD的影响因素(OR=1.013，95%CI：1.004~1.023，P＜0.05)。 结论 血清ALP升高是T2DM合并NFALD的危险因素，且与高血糖、胰岛素抵抗、高血脂密切相关，可能在T2DM和NFALD疾病的发生发展中起一定作用。 Abstract:Objective To investigate the association between serum alkaline phosphatase (ALP) and type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD). Methods A total of 599 patients with T2DM who were hospitalized in Department of Endocrinology, Affiliated Hospital of Jiangsu University, from July 2016 to December 2018 were enrolled as subjects. According to the presence or absence of NAFLD, the patients were divided into NAFLD group with 286 patients and non-NAFLD group with 313 patients, and according to the results of abdominal ultrasound, the patients with NAFLD were divided into mild group with 111 patients, moderate group with 105 patients, and severe group with 70 patients. General clinical data were compared between groups. The independent samples t- test was used for comparison of normally distributed continuous data between two groups, and an analysis of variance was used for comparison between three groups; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison between three groups; the chi-square test was used for comparison of categorical data between groups. Pearson correlation analysis and Spearman correlation analysis were used to investigate the correlation between ALP and clinical indices, and a logistic regression analysis was used to investigate the influencing factors for NAFLD. Results Compared with the non-NAFLD group, the NAFLD group had significantly higher proportion of patients with history of hypertension (χ2=7.864, P < 0.05), systolic blood pressure (t=-2.226, P < 0.05), diastolic blood pressure (t=-3.800, P < 0.05), body mass index (BMI) (t=-11.842, P < 0.05), waist circumference (WC) (t=-9.150, P < 0.05), fasting insulin (FINS) (Z=-6.173, P < 0.05), fasting C-peptide (t=-5.419, P < 0.05), serum uric acid (t=-4.957, P < 0.05), low-density lipoprotein cholesterol (t=-2.702, P < 0.05), triglyceride (Z=-9.376, P < 0.05), total cholesterol (TC) (t=-3.016, P < 0.05), Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (Z=-5.794, P < 0.05), alanine aminotransferase (ALT) (Z=-6.737, P < 0.05), aspartate aminotransferase (AST) (Z=-4.389, P < 0.05), gamma-glutamyl transpeptidase (GGT) (Z=-7.764, P < 0.05), and ALP (t=-2.833, P < 0.05), as well as significantly lower age (t=2.184, P < 0.05) and high-density lipoprotein cholesterol (Z=-5.273, P < 0.05). The severity of NAFLD (mild, moderate or severe) was positively correlated with age (rs=0.140, P < 0.05), BMI (rs=0.239, P < 0.05), WC (rs=0.222, P < 0.05), FINS (rs=0.191, P < 0.05), HOMA-IR (rs=0.218, P < 0.05), ALT (rs=0.188, P < 0.05), AST (rs=0.279, P < 0.05), GGT (rs=0.202, P < 0.05), and ALP (rs=0.361, P < 0.05). In the patients with T2DM and NAFLD, ALP was positively correlated with HbAlc (r=0.149, P < 0.05), fasting plasma glucose (r=0.146, P < 0.05), HOMA-IR (rs=0.132, P < 0.05), TC (r=0.151, P < 0.05), ALT (rs=0.210, P < 0.05), AST (rs=0.192, P < 0.05), and GGT (rs=0.297, P < 0.05). The logistic regression analysis showed that ALP was an influencing factor for NAFLD in patients with T2DM (odds ratio=1.013, 95% confidence interval: 1.004-1.023, P < 0.05). Conclusion Elevated serum ALP is a risk factor for T2DM with NAFLD and is closely associated with hyperglycemia, insulin resistance, and hyperlipemia, and ALP may play a role in the development and progression of T2DM and NAFLD. -
非酒精性脂肪性肝病(NAFLD)是指除外过量饮酒和其他明确的损肝因素所致的肝细胞内脂肪沉积，全球2型糖尿病(T2DM)患者NAFLD患病率约为55.5%。NAFLD与高血糖、胰岛素抵抗、血脂异常等密切相关，T2DM合并NAFLD患者心血管疾病、肾脏病变等风险明显增加且更为严重[1-3]。ALP是一种广泛存在于人体组织中的一种酶，研究[4]显示ALP与胰岛素抵抗(IR)呈正相关，可导致基础状态下葡萄糖过剩，T2DM患者血清ALP活性升高，ALP增高是T2DM的独立危险因素。ALP在肝脏和骨骼中活性较高，通常作为胆汁淤积和骨代谢的指标，其在NAFLD中也可出现升高。在T2DM人群中，有关血清ALP与NAFLD关系的报道甚少，本研究旨在探讨ALP是否为T2DM合并NAFLD的危险因素，为相关疾病的早期防治提供一定的依据。
1. 资料与方法
1.1 研究对象
选取2016年7月—2018年12月在本院内分泌科就诊的T2DM患者599例(其中男320例，女279例)，平均年龄(63.32±11.30)岁。T2DM诊断符合1999年世界卫生组织糖尿病的诊断标准及分型标准[5]。根据超声检查结果将患者分为NAFLD组和非NAFLD组，NAFLD的诊断符合《非酒精性脂肪性肝病防治指南(2018年更新版)》[2]。排除标准：(1)1型糖尿病、特殊类型糖尿病、糖尿病急性严重代谢紊乱、急性感染；(2)骨骼系统疾病、慢性肾脏疾病；(3)病毒性肝炎、自身免疫性肝炎、肝豆状核变性、肝硬化等慢性肝病及肝脏恶性肿瘤、胆道疾病；(4)过度饮酒：饮酒折合乙醇量男性＞30 g/d(＞210 g/周)，女性＞20 g/d(＞140 g/周)；(5)服用噻唑烷二酮类药物、糖皮质激素、降脂药、丙戊酸钠、奥氮平等；(6)垂体前叶功能减退、甲状腺功能减退、性腺功能减退、甲状旁腺功能亢进、炎症性肠病、全胃肠外营养等全身性疾病[2]。
1.2 NAFLD超声分级标准
(1) 肝区近场回声弥漫性增强(强于肾脏和脾脏)远场回声逐渐衰减；(2)肝内管道结构显示不清；(3)肝脏轻至中度肿大，边缘角圆钝；(4)彩色多普勒血流显象提示肝内彩色血流信号减少或不易显示，但肝内血管走向正常；(5)肝右叶包膜及横膈回声显示不清或不完整。具备上述第1项及第2~4项中一项者为轻度脂肪肝；具备上述第1项及第2~4项中两项者为中度脂肪肝；具备上述第1项以及2~4项中两项和第5项者为重度脂肪肝[6]。
1.3 研究方法
1.3.1 一般资料测量
采用统一标准测量T2DM患者一般临床资料包括身高、体质量、腰围(WC)、收缩压(SBP)和舒张压(DBP)；收集患者性别、年龄、糖尿病病程、吸烟史、高血压病史。
1.3.2 生化指标检测
所有受试者于试验前一晚禁食12 h，于第2日清晨空腹状态下抽取静脉血检测血清ALP、糖化血红蛋白(HbA1c)、空腹血糖(FPG)、空腹胰岛素(FIns)、空腹C肽(FC-P)、尿酸(SUA)、GGT、ALT、AST、TC、TG、HDL-C、LDL-C。BMI=体质量/身高2(kg/m2)；稳态模型评估胰岛素抵抗指数(HOMA-IR)=空腹血糖×空腹胰岛素/22.5。
1.3.3 肝脏彩超检测
使用LOGIQ-9全身彩色多普勒诊断仪器，由超声科专业医生对受试者行空腹状态下腹部超声检查，观察其大小形态、肝脏回声及血流情况等。
1.4 统计学方法
采用SPSS 22.0对资料行统计分析。正态分布计量资料以x±s表示，两组间比较采用t检验，多组间比较使用单因素方差分析；非正态分布计量资料以M(P25~P75)表示，两组间比较采用非参数Mann Whitney U检验，多组间比较使用Kruskal-Wallis H秩和检验；计数资料组间比较采用χ2检验。采用Pearson相关分析法和Spearman相关分析法进行相关性分析。采用二元Logistic回归分析T2DM发生NAFLD的影响因素。P＜0.05为差异具有统计学意义。
2. 结果
2.1 两组一般资料及生化指标比较
NAFLD组高血压病史所占比例、SBP、DBP、BMI、WC、FIns、FC-P、SUA、LDL-C、TG、TC、HOMA-IR、ALT、AST、GGT、ALP均高于非NAFLD组(P值均＜0.05)。NAFLD组年龄、HDL-C低于非NAFLD组(P值均＜0.05)。两组间性别、病程、有吸烟史者所占比例、HbA1c、FPG比较，差异均无统计学意义(P值均＞0.05)(表 1)。
表 1 两组一般资料及生化指标比较Table 1. Comparison of general data between groups项目 non-NAFLD组(n=313) NAFLD组(n=286) 统计值 P值 男性[例(%)] 179(57.2) 141(49.3) χ2= 3.737 0.053 年龄(岁) 64.28±11.15 62.27±11.38 t=2.184 0.029 病程(月) 120(36~192) 120(36~159) Z=-1.365 0.172 BMI(kg/m2) 23.51±2.99 26.49±3.18 t=-11.842 ＜0.001 吸烟史[例(%)] 67(21.4) 60(21.0) χ2=0.016 0.898 高血压病史[例(%)] 174(55.6) 191(66.8) χ2=7.864 0.005 SBP(mmHg) 133.63±15.27 136.44±15.58 t=-2.226 0.026 DBP(mmHg) 78.62±8.77 81.47±9.58 t=-3.800 ＜0.001 WC(cm) 87.46±9.88 94.54±8.98 t=-9.150 ＜0.001 HbA1c(%) 8.89±2.13 8.93±1.73 t=-0.279 0.781 FPG(mmol/L) 9.69±3.71 9.50±3.12 t=0.684 0.495 FIns(μIU/L) 6.25(3.62~11.14) 10.05(5.41~16.72) Z=-6.173 ＜0.001 FC-P(μg/L) 1.74±0.96 2.18±1.04 t=-5.419 ＜0.001 SUA(μmol/L) 269.37±84.92 305.03±91.13 t=-4.957 ＜0.001 LDL-C(mmol/L) 2.54±0.86 2.72±0.75 t=-2.702 0.007 HDL-C(mmol/L) 1.09(0.88~1.34) 0.95(0.81~1.14) Z=-5.273 ＜0.001 TG(mmol/L) 1.28(0.96~1.79) 1.86(1.43~2.69) Z=-9.376 ＜0.001 TC(mmol/L) 4.61±1.10 4.86±0.98 t=-3.016 0.003 HOMA-IR 2.77(1.41~4.44) 3.92(2.19~6.71) Z=-5.794 ＜0.001 ALT(U/L) 14.80(11.05~21.90) 20.20(14.68~30.40) Z=-6.737 ＜0.001 AST(U/L) 14.70(11.35~17.95) 16.90(12.38~23.33) Z=-4.389 ＜0.001 GGT(U/L) 19.00(14.30~28.00) 27.60(20.00~43.55) Z=-7.764 ＜0.001 ALP(U/L) 69.73±19.94 74.71±23.03 t=-2.833 0.005 2.2 NAFLD严重程度与各指标相关性分析
随着脂肪肝严重程度的加重，T2DM合并NAFLD患者BMI、WC、FIns、HOMA-IR、ALT、AST、GGT、ALP水平均明显升高(P值均＜0.05)(表 2)。相关性分析显示，NAFLD的脂肪肝严重程度(轻、中、重)与年龄(rs=0.140，P=0.018)、BMI(rs=0.239，P＜0.001)、WC(rs=0.222，P＜0.001)、FIns(rs=0.191，P=0.001)、HOMA-IR(rs=0.218，P＜0.001)、ALT(rs=0.188，P=0.001)、AST(rs=0.279，P＜0.001)、GGT(rs=0.202，P=0.001)、ALP(rs=0.361，P＜0.001)水平呈正相关。
表 2 轻中重度NAFLD患者临床资料比较Table 2. Comparison of general data among groups in patients with NAFLD项目 轻度NAFLD组(n=111) 中度NAFLD组(n=105) 重度NAFLD组(n=70) 统计值 P值 男性[例(%)] 58(52.3) 56(53.3) 27(38.6) χ2=4.294 0.117 年龄(岁) 60.5±10.6 63.0±12.0 64.1±11.4 F=2.538 0.081 病程(月) 120(36~168) 108(29~144) 120(33~156) χ2=0.442 0.802 BMI(kg/m2) 25.48±2.59 26.88±2.991) 27.52±3.831) F=10.731 ＜0.001 SBP(mmHg) 136.16±15.64 134.51±14.55 139.76±16.66 F=2.429 0.090 DBP(mmHg) 81.10±9.33 81.57±9.68 81.91±9.92 F=0.163 0.849 WC(cm) 92.17±7.37 95.33±8.381) 97.12±11.141) F=7.502 0.001 HbA1c(%) 8.79±1.72 8.90±1.67 9.22±1.85 F=1.388 0.251 FPG(mmol/L) 9.35±3.04 9.28±3.12 10.06±3.21 F=1.551 0.214 FIns(μIU/L) 7.38(4.61~14.94) 10.25(5.69~16.22) 11.65(7.53~19.62)1) χ2=10.512 0.005 FC-P(μg/L) 2.12±1.07 2.19±1.00 2.28±1.05 F=0.524 0.593 SUA(μmol/L) 293.99±82.32 321.08±88.00 298.46±105.81 F=2.654 0.072 LDL-C(mmol/L) 2.76±0.73 2.66±0.77 2.76±0.77 F=0.603 0.548 HDL-C(mmol/L) 0.95(0.82~1.14) 0.93(0.80~1.11) 0.99(0.82~1.21) χ2=1.749 0.417 TG(mmol/L) 1.84(1.37~2.87) 1.77(1.47~2.59) 1.92(1.45~3.16) χ2=0.679 0.712 TC(mmol/L) 4.83±0.96 4.74±0.91 5.10±1.08 F=2.956 0.054 HOMA-IR 3.32(1.83~5.55) 3.90(2.34~6.51) 5.47(2.96~9.53)1) χ2=14.183 0.001 ALT(U/L) 18.00(13.60~27.60) 22.00(15.10~31.30) 23.95(16.00~42.23)1) χ2=10.453 0.005 AST(U/L) 14.00(11.50~18.40) 18.40(13.00~25.30)1) 20.05(14.25~27.08)1) χ2=22.423 ＜0.001 GGT(U/L) 23.00(17.00~38.80) 27.90(21.05~39.50) 34.50(21.65~55.43)1) χ2=11.791 0.003 ALP(U/L) 65.72±16.63 73.71±20.941) 90.44±26.581)2) F=29.920 ＜0.001 注：与轻度NAFLD组比较，1)P＜0.01；与中度NAFLD组比较，2)P＜0.01。 2.3 T2DM合并NAFLD患者ALP与临床指标的相关性分析
相关分析显示，T2DM合并NAFLD患者ALP与HbA1c、FPG、HOMA-IR、TC、ALT、AST、GGT呈正相关(P值均＜0.05)(表 3)。
表 3 NAFLD患者ALP与临床各指标的相关性分析Table 3. Correlation analysis between ALP and clinical indicators in patients with NAFLD项目 r或rs值 P值 HbA1c 0.149 0.012 FPG 0.146 0.014 HOMA-IR 0.132 0.025 TC 0.151 0.011 ALT 0.210 ＜0.001 AST 0.192 0.001 GGT 0.297 ＜0.001 2.4 T2DM患者NAFLD影响因素的Logistic回归分析
以是否出现NAFLD为因变量，以年龄、BMI、高血压病史、FPG、FC-P、TC、TG、HDL-C、LDL-C、SUA、HOMA-IR、ALP为自变量，行二元Logistic回归分析，结果显示，年龄、BMI、FC-P、LDL-C、TG、ALP均为T2DM患者发生NAFLD的影响因素(表 4)。
表 4 Logistic回归分析NAFLD的影响因素Table 4. Logistic regression analysis of the influencing factors for NAFLD因素 β值 SE Wald OR 95%CI P值 年龄 -0.030 0.010 8.527 0.971 0.951~0.990 0.003 BMI 0.298 0.037 63.596 1.347 1.252~1.450 ＜0.001 FC-P 0.267 0.111 5.807 1.307 1.051~1.624 0.016 LDL-C 1.332 0.470 8.023 3.787 1.507~9.516 0.005 TG 0.685 0.167 16.803 1.984 1.430~2.752 ＜0.001 ALP 0.013 0.005 7.444 1.013 1.004~1.023 0.006 3. 讨论
ALP是一种常见的广泛存在于微生物和动植物中的酶，在人体内有四种ALP同工酶，包括组织非特异性ALP(TNAP)、肠型ALP、生殖细胞型ALP以及胎盘型ALP。TNAP主要在肝脏、肾脏和骨骼组织中表达，占血清总ALP活性的90%以上[7]。在小鼠3T3-L1前脂肪细胞中的研究[8]发现，TNAP水平在脂肪生成过程中升高，但在脂肪生成开始加入TNAP抑制剂后，TNAP活性和脂质积累均减少；同时在原代培养的人前脂肪细胞中也观察到类似现象。此外，更多证据表明ALP活性存在于大鼠脂肪组织、兔前脂肪细胞和人脂肪细胞中，TNAP敲除小鼠也表现出脂肪量的减少。TNAP除了参与调节脂肪细胞内脂质积累，也在肝细胞和肾上腺细胞的脂质积累中发挥作用，提示TNAP可能参与了多种不同类型细胞中的脂质积累[9-10]。一项研究[11]纳入了14 393例无糖尿病的高血压病患者，平均随访4.5年后发现血清ALP升高与IR相关，并且增加了糖尿病的患病风险。本研究结果显示，在T2DM合并NAFLD的患者中，ALP与HbA1c、FPG、HOMA-IR、TC、ALT、AST、GGT呈正相关，提示ALP增加可能与IR、血脂异常等多种致NAFLD风险密切相关。
据估计，2016年—2030年我国NAFLD的患病人数将从2.46亿人增加至约3.14亿人，NAFLD患病率的迅速增长导致高血糖、IR、血脂异常、肝硬化、肝癌和亚临床炎症的增加，加剧如糖尿病、肥胖、心血管疾病和癌症等非传染性疾病的负担[1, 12]。本研究发现，NAFLD组BMI、WC、FIns、FC-P、LDL-C、TG、TC、HOMA-IR、ALP水平均高于非NAFLD组。随着脂肪肝严重程度的加重，T2DM合并NAFLD患者ALP水平均明显升高；NAFLD的脂肪肝严重程度与ALP水平呈正相关。Logistic回归分析表明，在调整了相关的NAFLD危险因素之后，年龄、BMI、FC-P、LDL-C、TG、ALP均为T2DM患者发生NAFLD的影响因素。NAFLD是肝脏能量代谢不平衡的表现，肝脏有将能量氧化为CO2或输出为极低密度脂蛋白的能力，但是过多的能量主要以碳水化合物和脂肪的形式进入肝脏后，导致TG在肝脏中的积累，因此NAFLD在肥胖者中广泛存在[13]。迄今为止，IR被认为是NAFLD发病及进展的主要机制。在IR状态下，肝脏失去在胰岛素作用下抑制肝葡萄糖生成的能力并且通过激活Notch信号通路增强脂肪从头合成。脂肪在肝脏的积累是由于游离脂肪酸(FFA)的摄取、合成、输出和氧化受损造成的。在NAFLD患者中，因为脂肪组织抑制脂肪分解的功能受损，所以肝脏脂肪变性的数量与血浆游离FFA水平的增加相关[14]。FFA导致JNK信号通路的激活，从而引起细胞应激、炎症、凋亡和线粒体功能障碍。此外，JNK信号通路使PPARγ磷酸化，加剧了脂毒性和肝炎症[15]。近年研究[16]表明，C肽也与NAFLD密切相关，可能与IR和C肽本身生物功能有关。本研究中年龄较长者NAFLD的发生率较低，考虑随着年龄的增长，脂肪组织储存脂肪能力下降、肝纤维化比例升高以及接受更长久的T2DM治疗干预等原因对结果造成一定的影响[17]。
综上所述，血清ALP水平与血糖、IR、脂代谢紊乱密切相关，ALP是T2DM合并NAFLD的危险因素，ALP可能参与了T2DM和NAFLD的发生发展。能否进行预防性用药干预ALP水平使NAFLD得到缓解，值得后续进一步研究。另外，本研究样本量偏少，为单中心横断面研究，可能存在选择偏倚，可进一步扩大样本量证实，ALP在NAFLD中的具体作用机制也需更加深入的研究。
-
表 1 两组一般资料及生化指标比较
Table 1. Comparison of general data between groups
项目 non-NAFLD组(n=313) NAFLD组(n=286) 统计值 P值 男性[例(%)] 179(57.2) 141(49.3) χ2= 3.737 0.053 年龄(岁) 64.28±11.15 62.27±11.38 t=2.184 0.029 病程(月) 120(36~192) 120(36~159) Z=-1.365 0.172 BMI(kg/m2) 23.51±2.99 26.49±3.18 t=-11.842 ＜0.001 吸烟史[例(%)] 67(21.4) 60(21.0) χ2=0.016 0.898 高血压病史[例(%)] 174(55.6) 191(66.8) χ2=7.864 0.005 SBP(mmHg) 133.63±15.27 136.44±15.58 t=-2.226 0.026 DBP(mmHg) 78.62±8.77 81.47±9.58 t=-3.800 ＜0.001 WC(cm) 87.46±9.88 94.54±8.98 t=-9.150 ＜0.001 HbA1c(%) 8.89±2.13 8.93±1.73 t=-0.279 0.781 FPG(mmol/L) 9.69±3.71 9.50±3.12 t=0.684 0.495 FIns(μIU/L) 6.25(3.62~11.14) 10.05(5.41~16.72) Z=-6.173 ＜0.001 FC-P(μg/L) 1.74±0.96 2.18±1.04 t=-5.419 ＜0.001 SUA(μmol/L) 269.37±84.92 305.03±91.13 t=-4.957 ＜0.001 LDL-C(mmol/L) 2.54±0.86 2.72±0.75 t=-2.702 0.007 HDL-C(mmol/L) 1.09(0.88~1.34) 0.95(0.81~1.14) Z=-5.273 ＜0.001 TG(mmol/L) 1.28(0.96~1.79) 1.86(1.43~2.69) Z=-9.376 ＜0.001 TC(mmol/L) 4.61±1.10 4.86±0.98 t=-3.016 0.003 HOMA-IR 2.77(1.41~4.44) 3.92(2.19~6.71) Z=-5.794 ＜0.001 ALT(U/L) 14.80(11.05~21.90) 20.20(14.68~30.40) Z=-6.737 ＜0.001 AST(U/L) 14.70(11.35~17.95) 16.90(12.38~23.33) Z=-4.389 ＜0.001 GGT(U/L) 19.00(14.30~28.00) 27.60(20.00~43.55) Z=-7.764 ＜0.001 ALP(U/L) 69.73±19.94 74.71±23.03 t=-2.833 0.005 
下载: 导出CSV
表 2 轻中重度NAFLD患者临床资料比较
Table 2. Comparison of general data among groups in patients with NAFLD
项目 轻度NAFLD组(n=111) 中度NAFLD组(n=105) 重度NAFLD组(n=70) 统计值 P值 男性[例(%)] 58(52.3) 56(53.3) 27(38.6) χ2=4.294 0.117 年龄(岁) 60.5±10.6 63.0±12.0 64.1±11.4 F=2.538 0.081 病程(月) 120(36~168) 108(29~144) 120(33~156) χ2=0.442 0.802 BMI(kg/m2) 25.48±2.59 26.88±2.991) 27.52±3.831) F=10.731 ＜0.001 SBP(mmHg) 136.16±15.64 134.51±14.55 139.76±16.66 F=2.429 0.090 DBP(mmHg) 81.10±9.33 81.57±9.68 81.91±9.92 F=0.163 0.849 WC(cm) 92.17±7.37 95.33±8.381) 97.12±11.141) F=7.502 0.001 HbA1c(%) 8.79±1.72 8.90±1.67 9.22±1.85 F=1.388 0.251 FPG(mmol/L) 9.35±3.04 9.28±3.12 10.06±3.21 F=1.551 0.214 FIns(μIU/L) 7.38(4.61~14.94) 10.25(5.69~16.22) 11.65(7.53~19.62)1) χ2=10.512 0.005 FC-P(μg/L) 2.12±1.07 2.19±1.00 2.28±1.05 F=0.524 0.593 SUA(μmol/L) 293.99±82.32 321.08±88.00 298.46±105.81 F=2.654 0.072 LDL-C(mmol/L) 2.76±0.73 2.66±0.77 2.76±0.77 F=0.603 0.548 HDL-C(mmol/L) 0.95(0.82~1.14) 0.93(0.80~1.11) 0.99(0.82~1.21) χ2=1.749 0.417 TG(mmol/L) 1.84(1.37~2.87) 1.77(1.47~2.59) 1.92(1.45~3.16) χ2=0.679 0.712 TC(mmol/L) 4.83±0.96 4.74±0.91 5.10±1.08 F=2.956 0.054 HOMA-IR 3.32(1.83~5.55) 3.90(2.34~6.51) 5.47(2.96~9.53)1) χ2=14.183 0.001 ALT(U/L) 18.00(13.60~27.60) 22.00(15.10~31.30) 23.95(16.00~42.23)1) χ2=10.453 0.005 AST(U/L) 14.00(11.50~18.40) 18.40(13.00~25.30)1) 20.05(14.25~27.08)1) χ2=22.423 ＜0.001 GGT(U/L) 23.00(17.00~38.80) 27.90(21.05~39.50) 34.50(21.65~55.43)1) χ2=11.791 0.003 ALP(U/L) 65.72±16.63 73.71±20.941) 90.44±26.581)2) F=29.920 ＜0.001 注：与轻度NAFLD组比较，1)P＜0.01；与中度NAFLD组比较，2)P＜0.01。
下载: 导出CSV
表 3 NAFLD患者ALP与临床各指标的相关性分析
Table 3. Correlation analysis between ALP and clinical indicators in patients with NAFLD
项目 r或rs值 P值 HbA1c 0.149 0.012 FPG 0.146 0.014 HOMA-IR 0.132 0.025 TC 0.151 0.011 ALT 0.210 ＜0.001 AST 0.192 0.001 GGT 0.297 ＜0.001
下载: 导出CSV
表 4 Logistic回归分析NAFLD的影响因素
Table 4. Logistic regression analysis of the influencing factors for NAFLD
因素 β值 SE Wald OR 95%CI P值 年龄 -0.030 0.010 8.527 0.971 0.951~0.990 0.003 BMI 0.298 0.037 63.596 1.347 1.252~1.450 ＜0.001 FC-P 0.267 0.111 5.807 1.307 1.051~1.624 0.016 LDL-C 1.332 0.470 8.023 3.787 1.507~9.516 0.005 TG 0.685 0.167 16.803 1.984 1.430~2.752 ＜0.001 ALP 0.013 0.005 7.444 1.013 1.004~1.023 0.006
下载: 导出CSV
-
[1] STEFAN N, CUSI K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes[J]. Lancet Diabetes Endocrinol, 2022, 10(4): 284-296. DOI: 10.1016/S2213-8587(22)00003-1. [2] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. [3] YOUNOSSI ZM, GOLABI P, DE AVILA L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801. DOI: 10.1016/j.jhep.2019.06.021. [4] XIONG T, ZHONG C, SUN G, et al. Early maternal circulating alkaline phosphatase with subsequent gestational diabetes mellitus and glucose regulation: a prospective cohort study in China[J]. Endocrine, 2019, 65(2): 295-303. DOI: 10.1007/s12020-019-01954-5. [5] World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus[R]. Geneva: WHO, 1999: 50. [6] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of clinical diagnosis and treatment for nonalcoholic fatty liver disease[J]. Chin Hepatol, 2006, 11(1): 68-70. DOI: 10.3969/j.issn.1008-1704.2006.01.032.中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 肝脏, 2006, 11 (1) : 68-70. DOI: 10.3969/j.issn.1008-1704.2006.01.032. [7] HUANG CW, WU TH, HSU HY, et al. Reappraisal of the role of alkaline phosphatase in hepatocellular carcinoma[J]. J Pers Med, 2022, 12(4): 518. DOI: 10.3390/jpm12040518. [8] BARTLETT CL, CAVE EM, CROWTHER NJ, et al. A new perspective on the function of Tissue Non-Specific Alkaline Phosphatase: from bone mineralization to intra-cellular lipid accumulation[J]. Mol Cell Biochem, 2022, 477(8): 2093-2106. DOI: 10.1007/s11010-022-04429-w. [9] CHIRAMBO GM, VAN NIEKERK C, CROWTHER NJ. The role of alkaline phosphatase in intracellular lipid accumulation in the human hepatocarcinoma cell line, HepG2[J]. Exp Mol Pathol, 2017, 102(2): 224-229. DOI: 10.1016/j.yexmp.2017.02.007. [10] CAVE E, CROWTHER NJ. Tissue non-specific alkaline phosphatase mediates the accumulation of cholesterol esters in the murine Y1 adrenal cortex cell line[J]. Ann Anat, 2020, 227: 151420. DOI: 10.1016/j.aanat.2019.151420. [11] ZHANG Y, ZHOU C, LI J, et al. Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults[J]. Cardiovasc Diabetol, 2020, 19(1): 186. DOI: 10.1186/s12933-020-01161-x. [12] MA HL, QUAN L, JIANG S. Analysis of clinical characteristics and risk factors in patients with nonal-coholic fatty liver disease complicated with type 2 diabetes mellitus[J]. China Med Herald, 2022, 19(21): 70-73, 82. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202221016.htm马海林, 权莉, 蒋升. 非酒精性脂肪性肝病合并2型糖尿病患者的临床特征及危险因素分析[J]. 中国医药导报, 2022, 19(21): 70-73, 82. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202221016.htm [13] LOOMBA R, FRIEDMAN SL, SHULMAN GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10): 2537-2564. DOI: 1016/j.cell.2021.04.015. [14] ARMANDI A, ROSSO C, CAVIGLIA GP, et al. Insulin resistance across the spectrum of nonalcoholic fatty liver disease[J]. Metabolites, 2021, 11(3): 155. DOI: 10.3390/metabo11030155. [15] SCORLETTI E, CARR RM. A new perspective on NAFLD: Focusing on lipid droplets[J]. J Hepatol, 2022, 76(4): 934-945. DOI: 10.1016/j.jhep.2021.11.009. [16] WANG N, WANG Y, ZHANG W, et al. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes[J]. Diabetes Metab Res Rev, 2020, 36(2): e3210. DOI: 10.1002/dmrr.3210. [17] LI YY, ZHAO L, DENG X, et al. Relationship between cardiometabolic index and risk of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]. Chin Gen Pract, 2021, 24(15): 1883-1888. DOI: 10.12114/j.issn.1007-9572.2021.00.433.李彦彦, 赵丽, 邓霞, 等. 2型糖尿病患者心脏代谢指数与非酒精性脂肪性肝病的关系研究[J]. 中国全科医学, 2021, 24(15): 1883-1888. DOI: 10.12114/j.issn.1007-9572.2021.00.433. 期刊类型引用(3)
1. 赵梓硕，朱玉光，马燕山，李志伟，景永帅，谢英花. 不同高脂饲料配方对建立非酒精性脂肪肝大鼠模型的影响. 中国临床药理学与治疗学. 2024(05): 543-553 . 
百度学术2. 罗志勇，刘斌. 利拉鲁肽联合达格列净治疗2型糖尿病合并NAFLD的临床效果. 中国医学创新. 2024(26): 72-76 . 百度学术3. 李非凡，徐岷. 血清碱性磷酸酶与高血压合并非酒精性脂肪性肝病的相关性分析. 热带医学杂志. 2024(10): 1444-1448 . 百度学术其他类型引用(4)
-
下载:
百度学术
